The Use of Oxytocin, Carbetocin and Buccal Misoprostol in Patients Undergoing Elective Cesarean Section (CS)

PHASE3CompletedINTERVENTIONAL
Enrollment

270

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Postpartum Hemorrhage
Interventions
DRUG

Syntocinon

Syntocinon ampoules (10 IU Oxytocin). (Novartis Pharma, Egypt) One ampoule 10 IU diluted in 10 ml normal saline and administered slowly (over 30- 60 seconds) intravenously just after delivery of the neonate during CS, followed by an intravenous drip of 20 IU oxytocin in 500 ml saline over 4 hours.

DRUG

Carbetocin

Carbetocin (Ampoule 100 μg/ml) . \[Pabal, Marketing Authorization Holder: Ferring GmbH (Gesellschaft mit beschränkter Haftung), Kiel ,Germany. Manufactured by DRAXIS Pharma , a division of specialty Pharmaceuticals Inc. Montreal ,Canada\] ,diluted in 10 ml normal saline and administered slowly (over 30- 60 seconds) intravenously just after delivery of the neonate during CS.

DRUG

Misoprostol

Misoprostol (200 mcg Tablet) \[Misotac, Sigma Pharmaceutical Industries, SAE, Egypt\] Two tablets (400 mcg) in the buccal space just after delivery of the neonate during CS.

Trial Locations (1)

Unknown

Ain Shams Maternity Hospital, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER

NCT02053922 - The Use of Oxytocin, Carbetocin and Buccal Misoprostol in Patients Undergoing Elective Cesarean Section (CS) | Biotech Hunter | Biotech Hunter